false 2023 FY --12-31 0001145604 0

 July 20, 2022

 2024-03-22

 nkph: VentureGrowthEquitiesMember

 2020-02-19
 2020-02-19

 nkph: CentennialVenturesMember

 2020-02-28
 2020-02-28

 nkph: NikaEuropeLtdMember

 2022-10-11

 us-gaap: SpinoffMember

 us-gaap: EmployeeRelocationMember
 srt: DirectorMember

 us-gaap: EmployeeSeveranceMember
 nkph: PhilRayMember

 us-gaap: EmployeeSeveranceMember
 nkph: ATerryMember

 us-gaap: EmployeeRelocationMember

 nkph: CEOMember

 nkph: CEOMember

 nkph: CEOMember

 nkph: VITALMember

 nkph: DimitarMember
 nkph: VITALMember

 nkph: VITALMember

 nkph: MICARMember

 nkph: DimitarMember
 nkph: MICARMember

 nkph: MICARMember

 2022-08-18

 nkph: NobleMember

 2022-04-25
 2022-04-25

 nkph: NobleMember

 2022-04-25

 nkph: FiziolongnPalmcarotilenMember

 nkph: FiziolongnPalmcarotilenMember

 nkph: MariyaRadivoevaMember

 nkph: MariyaRadivoevaMember

 nkph: KubratRadivoevMember

 nkph: KubratRadivoevMember

 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 FORM 10-K

 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year Ended December 31, 2023

 OR

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 For the transition period from_______________
 to_______________________

 Commission File No.: 000-56234

 NIKA PHARMACEUTICALS, INC. (Exact name of the small business issuer as specified in its
charter)

 colorado

 90-0292940

 (State or Other Jurisdiction of

 (I.R.S. Employer

 Incorporation or Organization)

 Identification No.)

 2269 Merrimack Valley Avenue, Henderson, NV 89044

 (Address of principal executive offices)

 (702) - 326-3615

 (Registrant's telephone number, including area code)

 (Former name, former address and former fiscal year, if changed
since last report)

 Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes
 No

 Indicate by check mark if the registrant is not required to
file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes
 No

 Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
 Yes No

 Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter
period that the registrant was required to submit such files).
 Yes
 No

 Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of "large accelerated filer," "accelerated filer,"
"smaller reporting company," and "emerging growth company" in Rule 12b-2 of the
Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the
 registrant has elected not to use the extended transition period for complying
 with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.

 Indicate by check mark whether the registrant has filed a
report on and attestation to its management's assessment of the effectiveness of
its internal control over financial reporting under Section 404(b) of the
Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm
that prepared or issued its audit report.

 Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
Yes
 No

 State the aggregate market value of the voting and non-voting
common equity held by non-affiliates on the last business day of the
registrant's most recently completed second fiscal quarter. N/A

 As of January 25, 2025, the Company's common stock is listed
under the symbol NKPH, on the OTC Markets PINK,

 As of March 22, 2024, there were 876,090,000 shares of the
issuer's common stock outstanding.

 Page

 Item 1.

 Business

 Item 1A.

 Risk
 Factors

 Item 1B.

 Unresolved
 Staff Comments

 Item 1C.

 Cybersecurity

 Item 2.

 Properties

 Item 3.

 Legal
 Proceedings

 Item 4.

 Mine Safety
 Disclosures

 PART
 II

 Item 5.

 Market for
 Registrant's Common Equity, Related Stockholder Matters and Issuer
 Purchases of Equity Securities

 Item 6.

 [Reserved]

 Item 7.

 Management's Discussion and Analysis of Financial Condition
 and Results of Operation

 Item 7A.

 Quantitative and Qualitative Disclosure About Market Risk

 Item 8.

 Financial
 Statements and Supplementary Data

 Item 9.

 Changes
 in and Disagreements with Accountants on Accounting and Financial
 Disclosure

 Item 9A.

 Controls
 and Procedures

 Item 9B.

 Other
 Information

 Item 9C.

 Disclosure Regarding Foreign Jurisdictions that Prevent
 Inspections.

 PART
 III

 Item 10.

 Directors, Executive Officers and Corporate Governance

 Item 11.

 Executive
 Compensation

 Item 12.

 Security
 Ownership of Certain Beneficial Owners and Management and Related
 Stockholder Matters

 Item 13.

 Certain
 Relationships and Related Transactions, and Director Independence

 Item 14.

 Principal
 Accountant Fees and Services

 PART
 IV

 Item 15.

 Exhibits
 and Financial Statement Schedules

 Item 16

 Form 10-K
 Summary

 Signeture

 ITEM 1. BUSINESS

 Forward-Looking Statements

 Unless the context indicates
otherwise, as used in this Annual Report, the terms "Nika," "we," "us," "our,"
"our company" and "our business" refer, to Nika Pharmaceuticals, Inc..,
including its subsidiaries. Certain statements, other than purely historical
information, including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the assumptions
upon which those statements are based, are "forward-looking statements." These
forward-looking statements generally are identified by the words "believes,"
"project," "expects," "anticipates," "estimates," "intends," "strategy," "plan,"
"may," "will," "would," "will be," "will continue," "will likely result," and
similar expressions. Forward-looking statements are based on current
expectations and assumptions that are subject to risks and uncertainties which
may cause actual results to differ materially from the forward-looking
statements Our ability to predict results or the actual effect of future plans
or strategies is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects include, but are not
limited to: changes in economic conditions, legislative/regulatory changes,
availability of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be considered
in evaluating forward-looking statements and undue reliance should not be placed
on such statements.

 Business Overview

 Nika Pharmaceuticals, Inc. was
incorporated in the State of Colorado on June 6, 2000. Pursuant to the terms of
a stock purchase agreement resulting in a change of control the Company is
changing its business to focus on the following.

 On April 7, 2022, the Company signed with "VITAL FE" Joint
Stock Company ("VITAL") an Exclusive Rights sAgreement for a term of 15 years for the production and
distribution of Thymus Nuclear Glycoprotein ("TNG"). VITAL holds the technology
to manufacture TNG and the intellectual property for Phase III Clinical Trial on
TNG, started in 1997 and completed in 1998 in Infectious Diseases Hospital,
Sofia on 20 patients suffering from AIDS in the advanced stages of the disease.
The results of the clinical trial show that TNG has a significant place in the
treatment of HIV.

 On April 7, 2022, signed with
 "MICAR 11" LTD. ("MICAR") an Exclusive Rights Agreement for a term of 15 years
 for the production and distribution of two dietary supplements, namely
 Carotilen and Physiolong. Carotilen is a dietary supplement
 in the form of soft gelatin capsules that improves and regulates the metabolism
 of the epithelial cells and protects them from degenerative alterations. It
 favorably affects embryonic development; the regulation of the growth and
 division of the cells; stimulates the growth of the bone tissue; favorably
 affects the function of the gonads; increases and maintains high level of the
 immune system. Physiolong is a dietary food supplement in the form of
 hard gelatin capsules, which serves as general stimulant for those in a period
 of convalescence, as well as in situations of high mental and physical loads,
and for the recovery in sports.

 On August 1, 2022, the Company
signed a Joint Business Agreement with Immunotech Laboratories BG, Ltd through
which the two companies are combining their efforts to realize the registration,
production and distribution of medicinal products based on the Inactivated
Pepsin Fraction ("IPF") platform with U.S. Patents N 7,479,538, 7,625,565,
8,066,982, 8,067,531, 8,309,072. The duration of the agreement is for a period
of 9 years and will be renewed automatically for another 9 years unless there
are reasonable objections to the renewal by one of the parties.

 On August 1, 2022, the Company
signed a Cooperation Agreement with Nika BioTechnology, Inc. (OTCMKTS: NIKA) a
Nevada Corporation. Pursuant to the agreement, 0ll development of the
prescription drug TNG, the dietary supplements Physiolong and Carotilen, as well
as any future acquired other patents for prescription drugs and dietary
supplements, shall be jointly developed by the parties. The costs of production
and distribution will be financed by both parties in equal parts. The net profit
– after deduction of all expenses and taxes – will be distributed between the
parties in equal parts. The agreement is for a period of 15 years.

 On August 31, 2022, the company
signed an Exclusive Rights Agreement with Dimitar Slavchev Savov through which
Nika is appointed as an exclusive representative for the production and sale of
additional 6 dietary supplements – Hypocholestin, Biodetoxin, Dry Boza, Fructin,
Anthocylen C, Silymaron - within the territories of Europe, Asia, Africa, South
America, North America and Australia.

 On October 11, 2022, the Company
acquired a 40% stake in Nika Europe, Ltd. through which the company will have a
firm foothold on the markets of Europe, Asia, and Africa. Nika Europe is
preparing the construction of a pharmaceutical factory that is comprised of
different manufacturing facilities for the production of drugs in injection,
tablet and other forms. The factory will have enough production capacity to
secure the needs of Nika.

 Implications of Being an Emerging Growth Company

 We qualify as an "emerging growth
company" as defined under the Securities Act. As a result, we are permitted to,
and intend to, rely on exemptions from certain disclosure requirements that are
otherwise applicable to public companies. These provisions include, but are not
limited to:

 •

 not being required to comply with the auditor
 attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002,
 as amended (or the Sarbanes-Oxley Act);

 •

 reduced disclosure obligations regarding
 executive compensation in our periodic reports, proxy statements and
 registration statements; and

 •

 exemptions from the requirements of holding a
 nonbinding advisory vote on executive compensation and stockholder
 approval of any golden parachute payments not previously approved.

 In addition, an emerging growth
company can take advantage of an extended transition period for complying with
new or revised accounting standards. This provision allows an emerging growth
company to delay the adoption of some accounting standards until those standards
would otherwise apply to private companies. We have elected to avail ourselves
of this extended transition period. We will remain an emerging growth company
until the earliest to occur of: (i) our reporting $1.07 billion or more in
annual gross revenues; (ii) the end of fiscal year 2024; (iii) our issuance, in
a three year period, of more than $1 billion in non-convertible debt; and (iv)
the end of the fiscal year in which the market value of our common stock held by
non-affiliates exceeded $700 million on the last business day of our second
fiscal quarter.

 ITEM 1A, RISK FACTORS

 We are a smaller reporting
company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as
such, are not required to provide the information under this Item.

 ITEM 1B. UNRESOLVED STAFF COMMENTS

 None

 ITEM 1C. CYBERSECURITY

 None

 ITEM 2. PROPERTIES

 We do not currently own any property.

 ITEM 3. LEGAL PROCEEDINGS

 There are no material claims, actions, suits, proceedings, or
investigations that are currently pending or, to the Company's knowledge, threatened by or against the Company or
respecting its operations or assets, or by or against any of the Company's
officers, directors, or affiliates.

 ITEM 4. MINE SAFETY DISCLOSURES

 Not applicable.

 ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES

 Market Information

 Our common stock is quoted under
the symbol "NKPH" on the Pink Open Market (f/k/a OTC Pink) published by OTC
Markets Group, Inc. ("OTC Pink"), where an established public trading market for
our common stock has not yet been established.

 Common Stock

 There are 2,700,000,000 shares of
Common Stock, $0.0001 par value, authorized, with 876,090,000 shares issued and
outstanding. The holders of Common Stock are entitled to one vote for each share
held on all matters submitted to a vote of shareholders. The holders of Common
Stock have no preemptive, subscription, redemption or conversion rights.

 Preferred Stock

 We have 10,000,000 shares of Preferred Stock, $0.0001 par
value, authorized of which 10,000,000 are issued and outstanding. Each
outstanding share of the series of Preferred Stock shall be entitled to one
thousand (1,000) votes on each matter submitted to a vote. Shares of Preferred
Stock shall, with respect to dividend rights, rights on redemption and rights on
liquidation, winding up and dissolution, rank pari passu with all classes of
Common Stock.

 Security Holders

 At March 13, 2024 there were
approximately 64 holders of record of our common stock, although we believe that
there are other persons who are beneficial owners of our common stock held in
street name. The transfer agent and registrar for our common stock is Securities
Transfer Corporation, 2901 N Dallas Parkway, Suite 380, Plano, Texas 75093.
Their telephone number is 469-633-0101.

 Dividend Policy

 We have never paid any cash
dividends and intend, for the foreseeable future, to retain any future earnings
for the development of our business. Our Board of Directors will determine our
future dividend policy on the basis of various factors, including our results of
operations, financial condition, capital requirements and investment
opportunities.

 Recent Issuance of Unregistered Securities

 None.

 Securities Authorized for Issuance Under Equity Compensation
Plans

 None.

 Item 6. [Reserved]

 Item 7. Management's Discussion and Analysis of
Financial Condition and Results of Operation

 The following discussion and
analysis of our consolidated financial condition and results of operations for
years ended December 31, 2023 and 2022 should be read in conjunction with the
consolidated financial statements and notes related thereto included elsewhere
in this report.

 Results of Operations for the Year Ended December 31,
2023 compared to the Year Ended December 31, 2022

 General and Administrative

 General and Administrative ("G&A") expenses have primarily
consisted of costs related to filing the Form 10-K and Form 10-Qs for the
Company, including audit and accounting expense and filing fees. For the years
ended December 31, 2023 and 2022 we had G&A expense of $64,833 and $33,175.
An increase of $31,118 or 92.3%. The increase can be attributed to an increase
in professional fees of $20,795 and IR expense of $20,000.

 Consulting expense

 Consulting expense was $0 and $150,000 for the years ended
December 31, 2023 and 2022, respectively. During the prior year the Company
issued common stock for services for total non-cash consulting expense of
$150,000.

 Development expense

 During the prior year the Company issued 10,000,000 shares of
preferred stock per the terms of two Exclusive Rights Agreement (Note 4). The
preferred shares were valued at $3,000,000.

 Net Loss

 During the year ended December 31, 2023, the Company incurred a
net loss of $64,833, compared to a net loss of $3,183,715 during the year ended
December 31, 2022. The decrease in net loss is due to expenses associated with
the issuance of common and preferred stock as discussed above.

 Liquidity and Capital Resources

 Operating Activities

 Net cash used in operating activities was $64,833 during the
year ended December 31, 2023, compared with $33,715 used in operating activities
during the year ended December 31, 2022.

 Investing Activities

 We neither generated nor used cash in investing activities
during the years ended December 31, 2023 and 2022.

 Financing Activities

 During the year ended December 31, 2023, we received $83,564 in
loan proceeds from a related party. During the year ended December 31, 2022, we
received $24,180 in loan proceeds from related parties and $10,000 from the sale
of common stock.

 Off-Balance Sheet Arrangements

 We have not entered into any off-balance sheet arrangements.

 Going Concern

 We have not yet generated
sustained profits from our operations. Our independent accountants have
expressed a "going concern" opinion. As of December 31, 2023, we had an
accumulated deficit of $3,400,247 and a net loss of $64,833 for the year ended
December 31, 2023.

 Management believes the Company
will continue to incur losses and negative cash flows from operating activities
for the foreseeable future and will need additional equity or debt financing to
sustain its operations until it can achieve profitability and positive cash
flows, if ever. Management plans to seek additional debt and/or equity financing
for the Company but cannot assure that such financing will be available on
acceptable terms.

 Our current management has agreed
to advance funds to the Company on an "as needed" basis. Should existing
management, stockholders or our affiliates refuse to advance needed funds,
however, we would be forced to turn to outside parties to either lend funds to us or buy our
securities. There is no assurance that we will be able to raise the necessary
funds, when needed, from outside sources.

 The Company's continuation as a
 going concern is dependent upon its ability to ultimately attain profitable
 operations, generate sufficient cash flow to meet its obligations, and obtain
 additional financing as may be required. Our auditors have included a "going
 concern" qualification in their Report of Independent Certified Public
 Accountants accompanying our audited consolidated financial statements appearing
 elsewhere herein which cites substantial doubt about our ability to continue as
 a going concern. Such a "going concern" qualification may make it more difficult
 for us to raise funds when needed. The outcome of this uncertainty cannot be
assured.

 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK

 We are a smaller reporting company as defined by Rule 12b-2 of
the Securities Exchange Act of 1934 and are not required to provide the
information under this item.

 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA

 NIKA PHARMACEUTICALS, INC. TABLE OF CONTENTS

 Report of Independent Registered Public Accounting Firm (Fruci
& Associates II, PLLC – PCAOB ID 0 5525)

 Report of Independent Registered Public Accounting Firm (BF
Borgers CPA PC - PCAOB ID 5041)

 Consolidated Balance Sheets as of December 31,
2023 and 2022

 Consolidated Statements of Operations for the years ended December
31, 2023 and 2022

 Consolidated Statement of Stockholders' Deficit for the years
ended December 31, 2023 and 2022

 Consolidated Statements of Cash Flows for the
years ended December 31, 2023 and 2022

 Notes to Consolidated Financial Statements

 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To the Board of Directors and Stockholders of Nika Pharmaceuticals, Inc.

 Opinion on the Financial Statements

 We have audited the accompanying consolidated balance sheet of Nika Pharmaceuticals, Inc. ("the Company") as of December 31, 2023, and the related consolidated statements of operations, changes in stockholders' (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

 Going Concern

 The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has no current operations and has generated no income to date. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 Critical Audit Matters

 Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

 Fruci & Associates II, PLLC – PCAOB ID #05525

 We have served as the Company's auditor since 2024.

 Spokane, Washington

 March 29, 2024

 Report of Independent Registered Public Accounting Firm

 To the shareholders and the board of directors of Nika Pharmaceuticals, Inc.

 Opinion on the Financial Statements

 We have audited the accompanying balance sheet of Nika Pharmaceuticals, Inc. (the "Company") as of December 31, 2022, the related statement of operations, stockholders' equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States.

 Substantial Doubt about the Company's Ability to Continue as a Going Concern

 The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company's significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 /s BF Borgers CPA PC

 BF Borgers CPA PC (PCAOB ID 5041)

 We have served as the Company's auditor from 2022 to 2023

 Lakewood, CO

 March 31, 2023

 NIKA PHARMACEUTICALS,
 INC.

 CONSOLIDATED
 BALANCE SHEETS

 December 31, 2023

 December 31, 2022

 ASSETS

 Current Assets:

 Cash

 $

 $

 Total current assets

 Total Assets

 $

 $

 LIABILITIES AND
 STOCKHOLDERS' DEFICIT

 Current Liabilities:

 Due to related party

 $

 101,745

 $

 18,180

 Total Current Liabilities

 101,745

 18,180

 Total Liabilities

 101,745

 18,180

 Commitments and contingencies

 —

 —

 Stockholders' Deficit:

 Preferred
 Stock; par value $ 0.0001;
 10,000,000 shares
 authorized; 10,000,000 shares issued and outstanding

 1,000

 1,000

 Common
 Stock; par value $ 0.0001;
 2,700,000,000
 shares
 authorized; 876,090,000 shares issued and outstanding

 87,609

 87,609

 Additional paid-in capital

 3,229,489

 3,229,489

 Accumulated deficit

 ( 3,400,247

)

 ( 3,335,414

)

 Total Stockholders' Deficit

 ( 82,149

)

 ( 17,316

)

 Total Liabilities and Stockholders' Deficit

 $

 $

 The accompanying notes are an integral part of these
consolidated financial statements.

 NIKA PHARMACEUTICALS, INC.

 CONSOLIDATED STATEMENTS OF OPERATIONS

 For the Years Ended

 December 31,

 2023

 2022

 Operating Expenses:

 General and
 administrative

 $

 64,833

 $

 33,715

 Consulting expense

 —

 150,000

 Development expense

 —

 3,000,000

 Total operating expenses

 64,833

 3,183,715

 Loss from operations

)

)

 Loss before provision for income taxes

)

)

 Provision for income taxes

 —

 —

 Net Loss

 $

)

 $

)

 Loss per share, basic and diluted

 $

 ( 0.00

)

 $

 ( 0.00

)

 Weighted average common shares outstanding, basic and
 diluted

 876,090,000

 723,953,014

 The accompanying notes are an integral part of these
consolidated financial statements.

 NIKA
 PHARMACEUTICALS, INC.

 CONSOLIDATED
 STATEMENT OF STOCKHOLDERS' DEFICIT

 FOR THE YEARS ENDED DECEMBER 31, 2023 AND
 2022

 Total

 Preferred Stock

 Common Stock

 Additional Paid

 Accumulated

 Stockholders'

 Shares

 Amount

 Shares

 Amount

 in Capital

 Deficit

 Equity

 Balances, December 31, 2021

 —

 $

 —

 396,090,000

 $

 39,609

 $

 88,471

 $

 ( 151,699

)

 $

 ( 23,619

)

 Forgiveness of related party loans

 —

 —

 —

 —

 30,018

 —

 30,018

 Common stock issued for cash

 —

 —

 30,000,000

 3,000

 7,000

 —

 10,000

 Common stock issued for services

 —

 —

 450,000,000

 45,000

 105,000

 —

 150,000

 Preferred stock issued for
 agreement

 1,000

 —

 —

 2,999,000

 —

 3,000,000

 Net loss

 —

 —

 —

 —

 —

)

)

 Balance, December 31, 2022

 1,000

 876,090,000

 87,609

 3,229,489

 ( 3,335,414

)

 ( 17,316

)

 Net loss

 —

 —

 —

 —

 —

)

)

 Balance, December 31, 2023

 $

 1,000

 876,090,000

 $

 87,609

 $

 3,229,489

 $

 ( 3,400,247

)

 $

 ( 82,149

)

 The accompanying notes are an integral part of these
consolidated financial statements.

 NIKA PHARMACEUTICALS,
 INC.

 CONSOLIDATED STATEMENTS OF CASH FLOWS

 For the Years
 Ended

 December 31,

 2023

 2022

 Cash flows from operating activities:

 Net Loss

 $

)

 $

)

 Adjustments to reconcile
 net loss to net cash used in operating activities:

 Preferred stock issued for
 development expense

 —

 3,000,000

 Common stock issued for services consulting

 —

 150,000

 Net cash used in operating
 activities

)

 ( 33,715

)

 Cash flows from investing
 activities:

 —

 —

 Cash flows from financing
 activities:

 Common
 stock issued for cash

 —

 10,000

 Loans from related party

 83,565

 24,180

 Net cash provided by financing activities

 83,565

 34,180

 Net change in cash

 18,732

 Cash, beginning of year

 Cash, end of year

 $

 $

 Supplemental disclosure of cash flow
 information:

 Cash paid
 for taxes

 $

 —

 $

 —

 Cash paid for interest

 $

 —

 $

 —

 Supplemental disclosure of non-cash investing
 and financing activity:

 Forgiveness of related party debt

 $

 —

 $

 30,018

 The accompanying notes are an integral part of these
consolidated financial statements

 NIKA PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
DECEMBER 31, 2023

 NOTE 1 – ORGANIZATION AND OPERATIONS

 Nika Pharmaceuticals, Inc. (the "Company" "Nika"), was
incorporated in the State of Colorado on June 8, 2000.

 On February 19, 2020, the Company created a subsidiary, Venture
Growth Equities, Inc., a Colorado corporation, of which 100 shares of common
stock was issued to the Company, making it a wholly owned subsidiary of the
Company. There has been no activity in the subsidiary.

 On February 28, 2020, the Company created a subsidiary,
Centennial Ventures, Inc., a Colorado corporation, of which 100 shares of common
stock was issued to the Company., making it a wholly owned subsidiary of the
Company. There has been no activity in the subsidiary.

 Mr. Ray was appointed as a Director, CEO, CFO, Secretary and
Treasurer of the Company and Mrs. A. Terry Ray, the wife of Mr. Ray, was
appointed as a Director of the Company.

 On January 6, 2022, Venture Growth Equities, Inc, was spun out
and signed over to Mr. Ray, thus no longer making it a subsidiary of the
Company.

 As a result of the purchase by Dimitar Slavchev Savov of a
total of 11,489,000 (87%) shares of common stock of the Corporation from Mr. Ray
and other shareholders, a change in control of the Company occurred as of April
1, 2022.

 Effective as of March 31, 2022, the board of directors
appointed Dimitar Slavchev Savov, and Clifford Redekop to serve as the Registrant's Directors.

 On March 31, 2022, Mr. Phil E. Ray resigned his position as a
Director, President and Chief Executive Officer of the Company.

 On March 31, 2022, Mrs. A. Terry. Ray resigned her position as
a Director and Secretary of the Company.

 On April 1, 2022, the board of directors accepted the
resignations of Mr. Phil E. Ray and Mrs. A. Terry Ray and appointed Dimitar
Slavchev Savov to serve as President, CEO, CFO and Clifford Redekop to serve as
Secretary of the Corporation.

 As of April 11, 2022, due to the acquisitions of Exclusive
Rights Agreements (Note 5) and the updated business scope, the Company is no
longer designated as a shell company.

 On May 17, 2022, the Company files Amended and Restated
Articles of Incorporation changing the name of the Company from Centennial
Growth Equities, Inc to Nika Pharmaceuticals, Inc.

 On October 11, 2022, the Company acquired a 40 % stake in Nika
Europe, Ltd. through which the company will have a firm foothold on the markets
of Europe, Asia, and Africa. Nika Europe is preparing the construction of a
pharmaceutical factory that is comprised of different manufacturing facilities
for the production of drugs in injection, tablet and other forms.

 NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 Basis of Presentation

 The Company's audited consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the
United States of America ("U.S. GAAP").

 Use of Estimates

 The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results may differ from those estimates.

 Concentrations of Credit Risk

 We maintain our cash in bank deposit accounts, the balances of
which at times may exceed federally insured limits. We continually monitor our
banking relationships and consequently have not experienced any losses in our
accounts. We believe we are not exposed to any significant credit risk on cash.

 Cash and Cash Equivalents

 For purposes of the statement of cash flows, the Company
considers all highly liquid instruments purchased with an original maturity of
three months or less to be cash equivalents. As of December 31, 2023 and 2022,
the Company had no cash equivalents.

 Principles of Consolidation

 The consolidated financial statements include the accounts of
the Company and its wholly owned subsidiary, Centennial Ventures, Inc. and Nika Europe, Ltd. There has been no activity in either
subsidiary as of December 31, 2023.

 Fair Value of Financial Instruments

 The Company follows paragraph 825-10-50-10 of the FASB
Accounting Standards Codification for disclosures about fair value of its
financial instruments and paragraph 820-10-35-37 of the FASB Accounting
Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of
its financial instruments. Paragraph 820-10-35-37 establishes a framework for
measuring fair value in accordance with U.S. GAAP and expands disclosures about
fair value measurements. To increase consistency and comparability in fair value
measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair
value hierarchy which prioritizes the inputs to valuation techniques, used to
measure fair value into three (3) broad levels. The fair value hierarchy gives
the highest priority to quoted prices (unadjusted) in active markets for
identical assets or liabilities and the lowest priority to unobservable inputs.
The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37
are described below.

 Level 1:

 Quoted market prices available in active
 markets for identical assets or liabilities as of the reporting date.

 Level 2:

 Pricing inputs other than quoted prices in
 active markets included in Level 1, which are either directly or
 indirectly observable as of the reporting date.

 Level 3:

 Pricing inputs that are generally unobservable
 inputs and not corroborated by market data.

 Income Taxes

 The Company follows Section 740-10-30 of the FASB Accounting
Standards Codification, which requires recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that have been
included in the financial statements or tax returns. Under this method, deferred
tax assets and liabilities are based on the differences between the financial
statement and tax bases of assets and liabilities using enacted tax rates in
effect for the fiscal year in which the differences are expected to reverse.
Deferred tax assets are reduced by a valuation allowance to the extent
management concludes it is more likely than not that the assets will not be
realized. Deferred tax assets and liabilities are measured using enacted tax
rates expected to apply to taxable income in the fiscal years in which those
temporary differences are expected to be recovered or settled. The effect on
deferred tax assets and liabilities of a change in tax rates is recognized in
the Statements of Income in the period that includes the enactment date.

 The Company follows section 740-10-25 of the FASB Accounting
Standards Codification ("Section 740-10-25") with regards to uncertainty income
taxes. Section 740-10-25 addresses the determination of whether tax benefits
claimed or expected to be claimed on a tax return should be recorded in the
financial statements. Under Section 740-10-25, the Company may recognize the tax
benefit from an uncertain tax position only if it is more likely than not that
the tax position will be sustained on examination by the taxing authorities,
based on the technical merits of the position. The tax benefits recognized in
the financial statements from such a position should be measured based on the
largest benefit that has a greater than fifty percent (50%) likelihood of being
realized upon ultimate settlement. Section 740-10-25 also provides guidance on
de-recognition, classification, interest and penalties on income taxes,
accounting in interim periods and requires increased disclosures. The Company
had no material adjustments to its liabilities for unrecognized income tax
benefits according to the provisions of Section 740-10-25.

 Stock-Based Compensation

 We account for equity-based transactions with employees and
non-employees under the provisions of FASB ASC Topic 718, "Compensation –
Stock Compensation" (Topic 718), which establishes that equity-based
payments to employees and non-employees are recorded at the grant date the fair
value of the equity instruments the entity is obligated to issue when the
employees and non-employees have rendered the requisite service and satisfied
any other conditions necessary to earn the right to benefit from the instruments. Topic 718 also states that
observable market prices of identical or similar equity or liability instruments
in active markets are the best evidence of fair value and, if available, should
be used as the basis for the measurement for equity and liability instruments
awarded in these share-based payment transactions. However, if observable market
prices of identical or similar equity or liability instruments are not
available, the fair value shall be estimated by using a valuation technique or
model that complies with the measurement objective, as described in FASB ASC
Topic 718.

 Net Income (Loss)Per Common Share

 Net income (loss) per common share is computed pursuant to
section 260-10-45 of the FASB Accounting Standards Codification. Basic net
income (loss) per common share is computed by dividing net income (loss) by the
weighted average number of shares of common stock outstanding during the period.
Diluted net income (loss) per common share is computed by dividing net income
(loss) by the weighted average number of shares of common stock including all
potentially outstanding shares of common stock during the period, unless the
effect is anti-dilutive. There are no potentially dilutive shares as of December
31, 2023 or 2022.

 Recent Accounting Pronouncements

 The Company has implemented all new applicable accounting
pronouncements that are in effect and applicable. These pronouncements did not
have any material impact on the financial statements unless otherwise disclosed,
and the Company does not believe that there are any other new accounting
pronouncements that have been issued that might have a material impact on its
financial position or results of operations.

 NOTE 3 - GOING CONCERN

 As reflected in the consolidated financial statements,
the Company has an accumulated deficit of $ 3,400,247 as of December 31, 2023,
has no current operations and has generated no income to date. These factors
raise substantial doubt about its ability to continue as a going concern.
 Company has an accumulated deficit of $3,382,790 as of June 30, 2023, has no current operations and has generated no income to date.
These factors raise substantial doubt about its ability to continue as a going concern. The
consolidated financial statements have been prepared assuming that the
Company will continue as a going concern. The Company may raise additional
capital through the sale of its equity securities, through offerings of debt
securities, or through borrowings from financial institutions. These
consolidated financial statements do not include any adjustments relating
to the recoverability and classification of recorded asset amounts or amounts
and classification of liabilities that might be necessary should the Company be
unable to continue as a going concern.

 NOTE 4 – RELATED PARTY TRANSACTIONS

 In conjunction with the sale of the majority shares of the
Company and the change in ownership, Mr. Ray forgave the $ 30,018 that was due to
him from the Company. The $ 30,018 has been credited to additional paid in
capital for the year ended December 31, 2022.

 During the year ended December 31, 2023 and 2022, Dimitar
Slavchev Savov, CEO, advanced the Company $ 83,565 and $ 24,180, respectively, to
pay for general operating expenses. As of December 31, 2023, the total amount
due to Mr. Savov is $ 101,745. The advance in non-interest bearing and due on
demand.

 Exclusive Rights Agreements

 On April 7, 2022, the Company signed with "VITAL FE" Joint
Stock Company ("VITAL") an Exclusive Rights Agreement for a term of 15 years for
the production and distribution of Thymus Nuclear Glycoprotein ("TNG"). VITAL
holds the technology to manufacture TNG and the intellectual property for Phase
III Clinical Trial on TNG, started in 1997 and completed in 1998 in Infectious
Diseases Hospital, Sofia on 20 patients suffering from AIDS in the advanced
stages of the disease. The results of the clinical trial show that TNG has a
significant place in the treatment of HIV. Under the terms of the agreement the
Company issued 8,000,000 shares of Preferred stock to be issued in the name of
Dimitar Slavchev Savov. Dimitar Savov is Managing Director and owner of 70 %
stake in VITAL. The shares were valued based on the equivalent number of votes
for common shares. The 8,000,000,000 (8 billion) equivalent common shares were
valued at $ 0.0003, the last sale price for common shares, (as there is currently
no trading volume), for total non-cash expense of $ 2,400,000.

 On April 7, 2022, the Company signed with "MICAR 11" LTD.
("MICAR") an Exclusive Rights Agreement for a term of 15 years for the
production and distribution of two dietary supplements, namely Carotilen
and Physiolong. Carotilen is a dietary supplement in the form of
soft gelatin capsules that improves and regulates the metabolism of the
epithelial cells and protects them from degenerative alterations. It favorably
affects embryonic development; the regulation of the growth and division of the
cells; stimulates the growth of the bone tissue; favorably affects the function
of the gonads; increases and maintains high level of the immune system.
 Physiolong is a dietary food supplement in the form of hard gelatin
capsules, which serves as general stimulant for those in a period of convalescence, as
well as in situations of high mental and physical loads, and for the recovery in
sports. Under the terms of the agreement the Company issued 2,000,000 shares of
Preferred stock to be issued in the name of Dimitar Slavchev Savov. MICAR is
wholly owned 100 % by Dimitar Savov and he acts as its Managing Director. The shares
were valued based on the equivalent number of votes for common shares. The
 2,000,000,000 (2 billion) equivalent common shares were valued at $ 0.0003, the
last sale price for common shares, (as there is currently no trading volume),
for total non-cash expense of $ 600,000.

 NOTE 5 - COMMON STOCK

 The Company and its Board of Directors approved a 30 for 1
stock dividend to be issued to all shareholders. The dividend became effective
on July 20, 2022. As a result, 846,887,000 shares of common stock were issued.
The stock dividend is considered to be a forward split in form; therefore, all
shares throughout these financial statements have been retroactively adjusted to
reflect the split.

 On August 18, 2022, the Company Amended its Articles of
Incorporation to change the par value of the common stock from $ 0.001 to
 $ 0.0001.

 On April 25, 2022, the Company issued
 150,000,000 shares of common stock to Noble Investment Corp. pursuant to the
terms of a Consulting Services Agreement for the goal of getting an active
trading symbol and placing the Company's common stock on OTC Markets. The shares
were valued at $ 0.00033, for total non-cash expense of $ 50,000.

 On April 26, 2022, the Company sold 30,000,000 shares of common
stock for $ 10,000 at $ 0.00033 per share.

 On April 26, 2022, the Company issued
 150,000,000 shares of common stock pursuant to the terms of an Intermediation
Agreement with the goal of getting national distribution of the Company's
dietary supplements Physiolong and Carotilen in the North American markets. The
shares were valued at $ 0.00033, for total non-cash expense of $ 50,000.

 On April 26, 2022, the Company issued
 75,000,000 shares of common stock to Mariya Radivoeva pursuant to the terms of a
Services Agreement with the goal of creating a coherent brand that reflects the
entry of Nika Pharmaceuticals. Inc. into the
pharmaceutical industry. The shares were valued at $ 0.00033, for total non-cash
expense of $ 25,000.

 On April 26, 2022, the Company issued
 75,000,000 shares of common stock to Kubrat Radivoev pursuant to the terms of a
Services Agreement with the goal of construction and maintenance of the
Company's own production facility. The shares were valued at $ 0.00033, for total
non-cash expense of $ 25,000.

 NOTE 6 – PREFERRED STOCK

 On April 8, 2022, the Company filed a certificate of
designation establishing the rights and preference of preferred stock with the
Secretary of State of Colorado, which modified the rights of owners of Preferred
Stock. Each outstanding share of the series of Preferred Stock shall be entitled
to one thousand (1,000) votes on each matter submitted to a vote. Shares of
Preferred Stock shall, with respect to dividend rights, rights on redemption and
rights on liquidation, winding up and dissolution, rank pari passu with all
classes of Common Stock.

 On August 18, 2022, the Company Amended its Articles of
Incorporation to change the par value of the preferred stock from $ 0.001 to
 $ 0.0001.

 Refer to Note 4 for preferred stock issued to a related party.

 NOTE 7 – OTHER EVENTS

 On August 31, 2022, the company signed an Exclusive Rights
Agreement with Dimitar Slavchev Savov through which Nika is appointed as an
exclusive representative for the production and sale of the dietary supplements
Hypocholestin, Dry Boza, Anthocylen C, Fructin, Biodetoxin, Sylimaron within the
territories of Europe, Asia, Africa, South America, North America and Australia.

 On August 1, 2022, the Company signed a Joint Business
Agreement with Immunotech Laboratories BG, Ltd. through which the two companies
are combining their efforts to realize the registration, production and
distribution of medicinal products based on the Inactivated Pepsin Fraction
("IPF") platform with U.S. Patents N 7,479,538, 7,625,565, 8,066,982,
8,067,531, 8,309,072. The duration of the agreement is for a period of 9
years and will renew automatically for another 9 years unless there are
reasonable objections to the renewal by one of the parties.

 On August 1, 2022, the Company signed a Cooperation Agreement
 with Nika BioTechnology, Inc. (OTCMKTS: NIKA) a Nevada Corporation. Pursuant to
 the agreement, all development of the prescription drug TNG, the dietary
 supplements Physiolong and Carotilen, as well as any future acquired other
 patents for prescription drugs and dietary supplements, shall be jointly
 developed by the parties. The costs of production and distribution will be
 financed by both parties in equal parts. The net profit – after deduction of all
 expenses and taxes – will be distributed between the parties in equal parts. The
agreement is for a period of 15 years.

 On October 11, 2022, the Company acquired a 40 % stake in Nika
Europe, Ltd. through which the company will have a firm foothold on the markets
of Europe, Asia, and Africa. Nika Europe is preparing the construction of a
pharmaceutical factory that is comprised of different manufacturing facilities
for the production of drugs in injection, tablet and other forms. The factory
will have enough production capacity to secure the needs of Nika.

 NOTE 8 – INCOME TAX

 Deferred taxes are provided on a liability method whereby
deferred tax assets are recognized for deductible temporary differences and
operating loss and tax credit carry forwards and deferred tax liabilities are
recognized for taxable temporary differences. Temporary differences are the
differences between the reported amounts of assets and liabilities and their tax
bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, it is more likely than not that some portion or all of
the deferred tax assets will not be realized. Deferred tax assets and
liabilities are adjusted for the effects of changes in tax laws and rates on the
date of enactment. The Company is using the U.S. federal income tax rate of 21 %.

 The provision for Federal income tax consists of the following
December 31:

 2023

 2022

 Federal income tax benefit attributable to:

 Current Operations

 $

 ( 14,000

)

 $

 ( 669,000

)

 Less: change in valuation allowance

 14,000

 669,000

 Net provision for Federal
 income taxes

 $

 —

 $

 —

 The cumulative tax effect at the expected rate of 21 % of
significant items comprising our net deferred tax amount is as follows:

 2023

 2022

 Deferred tax asset attributable to:

 Net operating loss carryover

 $

 ( 714,000

)

 $

 ( 700,000

)

 Less: valuation allowance

 714,000

 700,000

 Net deferred tax asset

 $

 —

 $

 —

 At December 31, 2023, the Company had net operating loss carry
forwards of approximately $ 714,000 maybe offset against future taxable income.
No tax benefit has been reported in the December 31, 2023 or 2022 financial statements since the potential tax benefit is
offset by a valuation allowance of the same amount.

 Due to the change in ownership provisions of the Tax Reform Act
of 1986, net operating loss carry forwards for Federal income tax reporting
purposes are subject to annual limitations. Should a change in ownership occur,
net operating loss carry forwards may be limited as to use in future years.

 ASC Topic 740 provides guidance on the accounting for
uncertainty in income taxes recognized in a company's financial statements.
Topic 740 requires a company to determine whether it is more likely than not
that a tax position will be sustained upon examination based upon the technical
merits of the position. If the more-likely-than-not threshold is met, a company
must measure the tax position to determine the amount to recognize in the
financial statements.

 The Company files income tax returns in the
U.S. federal jurisdiction, and various state and local jurisdictions.

 The Company includes interest and penalties arising from the
underpayment of income taxes in the statements of operations in the provision
for income taxes. As of December 31, 2023, the Company had no accrued interest
or penalties related to uncertain tax positions.

 NOTE 9 - SUBSEQUENT EVENTS

 Management has performed an evaluation of subsequent events
through the date that the financial statements were issued and has determined
that it has no material subsequent events to disclose in these consolidated
financial statements other than the following.

 As of January 25, 2024, the Company's common stock is listed on
OTC Markets PINK under the symbol, NKPH,

 On February 12, 2024, the Company signed an Agreement and Plan
of Merger (the "Merger") with Nika BioTechnology, Inc. (OTCMKTS: NIKA). Pursuant
to the Merger agreement Nika BioTechnology, Inc., (the Target company), will be
merged with and into the Company, the separate corporate existence of the
Target shall cease, and the Company shall continue as the surviving consolidated
entity.

 The Company will issue the target 204,205,027 shares of common
stock and 5,000,000 shares of Preferred stock in exchange for all of the issued
and outstanding shares of both the preferred and common stock of the Target
company.

 The transaction will be accounted for as a common control merger. As a result, the assets and liabilities assumed will be recorded on the Company's financial statements at their respective carry-over basis. Under ASC 805, "Business Combinations," the Company will record the common control merger as of the earliest date presented in financial statements for the upcoming quarter ended or March 31, 2024.

 On March 4, 2024, the Company amended its Articles of
Incorporation in which the authorized Preferred Stock was increased to
15,000,000 pursuant to the approved by the BOD and shareholders Plan and Merger
Agreement

 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL
 DISCLOSURES

 On February 14, 2024, the Company dismissed its independent
accountant B F Borgers CPA PC and engaged the firm of Fruci & Associates II,
PLLC to serve as the independent accountant to audit the company's financial
statements.

 We have had no "disagreements" (as such term is defined in
Item 304 of Regulation S-K) with our Accountant on any matter of accounting
principles or practices, financial statement disclosure, or auditing scope or
procedures.

 ITEM 9A. CONTROLS AND PROCEDURES

 Evaluation of Disclosure Controls and Procedures

 Under the supervision and with the participation of our
management, including our chief executive officer and principal financial
officer, we conducted an evaluation of our disclosure controls and procedures,
as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated
under the Securities Exchange Act of 1934, as amended, as of December 31, 2023.
Based on this evaluation, our chief executive officer and principal financial
officer have concluded such controls and procedures to be ineffective as of
December 31, 2023, to ensure that information required to be disclosed by the
issuer in the reports that it files or submits under the Act is recorded,
processed, summarized and reported, within the time periods specified in the
Commission's rules and forms and to ensure that information required to be
disclosed by an issuer in the reports that it files or submits under the Act is
accumulated and communicated to the issuer's management, including its principal
executive and principal financial officers, or persons performing similar
functions, as appropriate to allow timely decisions regarding required
disclosure.

 Management's Annual Report on Internal Control over
Financial Reporting

 Management is responsible for establishing and maintaining
adequate internal control over financial reporting, as such term is defined in
Rules 13a-15 (f) and 15d- 15 (f) under the Exchange Act, for the Company.

 Our internal control over financial reporting is the process
designed by and under the supervision of our CEO and CFO, or the persons
performing similar functions, to provide reasonable assurance regarding the
reliability of our financial reporting and the preparation of our financial
statements for external reporting in accordance with accounting principles generally accepted in the United States of America. In making
this assessment, our management used the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission ("COSO") in Internal Control
– Integrated Framework (2013).

 Under the supervision and with the participation of our CEO
 and CFO, or the persons performing similar functions, our management has
 assessed the effectiveness of our internal control over financial reporting as
 of December 31, 2023, and concluded that it is not effective because of the
material weakness described below:

 We are aware of the following material weaknesses in internal
control that could adversely affect the Company's ability to record, process,
summarize and report financial data:

 •

 Lack of an audit committee

 •

 Lack of segregation of duties

 A material weakness is a significant deficiency in one or
more of the internal control components that alone or in the aggregate precludes
our internal controls from reducing to an appropriately low level the risk that
material misstatements in our consolidated financial statements will not be
prevented or detected on a timely basis.

 This annual report does not include an attestation report of
our registered public accounting firm regarding internal control over financial
reporting. Management's report was not subject to attestation by the
registrant's registered public accounting firm pursuant to rules of the
Securities and Exchange Commission that permit the registrant to provide only
management's report in this annual report.

 Evaluation of Changes in Internal Control over Financial
Reporting

 During the year ended December 31, 2023, there were no
changes in our internal control over financial reporting identified in
connection with the evaluation required by paragraph (d) of Securities Exchange
Act Rules 13a-15 or 15d-15 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting. We
intend to recruit additional professionals, as our business conditions warrant,
to ensure that we include all necessary disclosure in our filings with the
Securities and Exchange Commission. Although we believe that these corrective
steps will enable management to conclude that the internal controls over our
financial reporting are effective when the staff is in place and trained, we
cannot provide assurance that these steps will be sufficient. We may be required
to expend additional resources to identify, assess and correct any additional
weaknesses in internal control.

 Important Considerations

 The effectiveness of our disclosure controls and procedures
and our internal control over financial reporting is subject to various inherent
limitations, including cost limitations, judgments used in decision making,
assumptions about the likelihood of future events, the soundness of our systems,
the possibility of human error, and the risk of fraud. Moreover, projections of
any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions and the risk
that the degree of compliance with policies or procedures may deteriorate over
time. Because of these limitations, there can be no assurance that any system of
disclosure controls and procedures or internal control over financial reporting
will be successful in preventing all errors or fraud or in making all material
information known in a timely manner to the appropriate levels of management.

 ITEM 9B. OTHER INFORMATION

 None.

 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT
PREVENT INSPECTIONS

 None.

 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE

 Identity of Officers and Directors

 The following table
 sets forth the names, ages, and titles of our executive officers and directors.

 Name

 Age

 Positions Held

 Since

 Dimitar Slavchev Savov

 President, CEO,
 CFO,
Director

 April 1, 2022

 Clifford Redekop

 Secretary&
 Director

 April 1, 2022

 Dimitar Slavchev Savov, Mr. Savov was born in Sofia,
Bulgaria on March 03, 1958. Savov graduated at the Dimitar A. Tsenov Academy
of Economics as a magister of economics with a specialty in accounting and
control with a minor in finance. During the political changes of November 10,
1989, Mr. Savov started a private business by creating the first private petrol
company and in a time of crisis with a lack of fuel, Mr. Savov created a chain
of the first private and modern gas stations in Bulgaria named Elpida 3. He
brought the company to a highly competitive level and practically saved Neftohim
Burgas from bankruptcy and Bulgaria from a fuel shortage. For the past 25 years,
Mr. Savov has invested and developed projects in the pharmaceutical field with
the goal to provide medicine for treatment of various life-threatening diseases
including AIDS, Cancer and others.

 Clifford Redekop, Mr, Redekop has an honors
liberal arts degree from Brock University and served in the Canadian Navy for 12
years. His first five years in the Navy were as a destroyer weapons officer and
the remainder as a public affairs officer. Postings and assignments were across
Canada and in Germany, and with many experiences as Defense Department spokesman
for multiple casualties and politically sensitive situations. Further education
included graduate school training in communications management and journalism.
After leaving the Navy, Redekop moved to Las Vegas, Nevada and became a
commercial real estate broker/investor/developer. Redekop is a licensed broker
in Nevada and Utah. Currently, and for the past six years, he has specialized in
assisting companies launch major expansions and in merging private businesses
into public companies. He has also worked with a number of Native American
Tribes in assisting them to bring economic development to their reservations.

 None of our directors or officers are related to each other.
There are no arrangements or understandings with any of our principal
stockholders, customers, suppliers, or any other person, pursuant to which any
of our directors or executive officers were appointed.

 Significant Employees

 We have no significant employees other than our officers.

 Director or Officer Involvement in Certain Legal
Proceedings

 During the past five (5) years, none of the following
occurred with respect to one of our present or former directors or executive
officers: (1) any bankruptcy petition filed by or against any business of which
such person was a general partner or executive officer either at the time of the
bankruptcy or within two (2) years prior to that
time; (2) any conviction in a criminal proceeding or being subject to a pending
criminal proceeding (excluding traffic violations and other minor offenses); (3)
being subject to any order, judgment or decree, not subsequently reversed,
suspended or vacated, of any court of any competent jurisdiction, permanently or
temporarily enjoining, barring, suspending or otherwise limiting his involvement
in any type of business, securities or banking activities; and (4) being found
by a court of competent jurisdiction (in a civil action), the Securities and
Exchange Commission or the Commodities Futures Trading Commission to have
violated a federal or state securities or commodities law, and the judgment has
not been reversed, suspended, or vacated.

 Director Independence

 We are not at this time required to have our board comprised
of a majority of "independent directors" as we are not subject to the listing
requirements of any national securities exchange or association,

 Section 16(a) Beneficial Ownership Reporting Compliance

 Section 16(a) of the Exchange Act requires a company's
directors, officers, and stockholders who beneficially own more than 10% of any
class of equity securities of the Company registered pursuant to Section 12 of
the Exchange Act (collectively referred to herein as the "Reporting Persons"),
to file initial statements of beneficial ownership of securities and statements
of changes in beneficial ownership of securities with respect to the company's
equity securities with the SEC. All Reporting Persons are required by SEC
regulation to furnish us with copies of all reports that such Reporting Persons
file with the SEC pursuant to Section 16(a).

 Based solely on review of the copies of such forms furnished to
Nika Pharmaceuticals' directors have not filed their reports as of the date of
this Annual Report.

 Code of Ethics

 We have not yet adopted a code of ethics that applies to our
principal executive officer, principal financial officer, principal accounting
officer or controller or persons performing similar functions.

 Corporate Governance

 There have been no changes in any state law or other procedures
by which security holders may recommend nominees to our board of directors. In
addition to having no nominating committee for this purpose, we currently have
no specific audit committee and no audit committee financial expert. Based on
the fact that our current business affairs are simple, any such committees are
excessive and beyond the scope of our business and needs.

 Audit Committee and Audit Committee Financial Expert

 We do not currently have an audit committee financial expert,
nor do we have an audit committee. Our board of directors, handles the functions
that would otherwise be handled by an audit committee. We do not currently have
the capital resources to pay director fees to a qualified independent expert who
would be willing to serve on our board and who would be willing to act as an
audit committee financial expert. As our business expands and as we appoint
others to our board of directors, we expect that we will seek a qualified
independent expert to become a member of our board of directors. Before
retaining any such expert our board would make a determination as to whether
such person is independent.

 ITEM 11, EXECUTIVE COMPENSATION

 Summary Compensation Table

 Change in

 Non-

 Pensions

 Equity

 Value and

 Incentive

 Nonqualifie

 Plan

 d Deferred

 All

 Name and

 Stock

 Option

 Compen

 Compensati

 Other

 Principal

 Salary

 Bonus

 Awards

 Awards

 sation

 on Earnings

 Compens

 Total

 Position

 Year

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 ation ($)

 ($)

 (a)

 (b)

 (c)

 (d)

 (e)

 (f)

 (g)

 (h)

 (i)

 (j)

 Dimitar

 Slavchev

 2023

 —

 —

 —

 —

 —

 —

 —

 —

 Savov (CEO,

 Director)

 2022

 —

 —

 —

 —

 —

 —

 —

 —

 Clifford

 Redekop

 2023

 —

 —

 —

 —

 —

 —

 —

 —

 (corporate

 secretary)

 2022

 —

 —

 —

 —

 —

 —

 —

 —

 Phil Ray

 (former

 2022

 —

 —

 —

 —

 —

 —

 —

 —

 CEO,

 Director)

 Alice Ray

 (former

 2022

 —

 —

 —

 —

 —

 —

 —

 —

 Director)

 No officer or director of the Company has received any
compensation in 2023 or 2022.

 Our directors and officers do not have unexercised options,
stock that has not vested, or equity incentive plan awards.

 We do not currently have a stock option plan. No individual
grants of stock options, whether or not in tandem with stock appreciation rights
known as SARs or freestanding SARs have been made to any executive officer or
any director since our inception; accordingly, no stock options have been
granted or exercised by any of the officers or directors since inception.

 We do not have any long-term incentive plans that provide
compensation intended to serve as incentive for performance. No individual
grants or agreements regarding future payouts under non-stock price-based plans
have been made to any executive officer or any director or any employee or
consultant since our inception; accordingly, no future payouts under non-stock
price-based plans or agreements have been granted or entered into or exercised
by our officer or director or employees or consultants since inception.

 To the knowledge of management, during the past five years,
no present or former director, or executive officer of the Company:

 1. Has filed a petition under the federal bankruptcy laws or
any state insolvency law, nor had a receiver, fiscal agent or similar officer
appointed by a court for the business or property of such person, or any
partnership in which he or she was a general partner at or within two years
before the time of such filing, or any corporation or business association of
which he or she was an executive officer at or within two years before the time
of such filing;

 2. Was convicted in a criminal proceeding or named subject
of a pending criminal proceeding (excluding traffic violations and other minor
offenses);

 3. Was the subject of any order, judgment or decree, not
subsequently reversed, suspended or vacated, of any court of competent
jurisdiction, permanently or temporarily enjoining him from or otherwise
limiting, the following activities:

 i. Acting as a futures commission merchant,
 introducing broker, commodity trading advisor, commodity pool operator,
 floor broker, leverage transaction merchant, associated person of any of
 the foregoing, or as an investment advisor, underwriter, broker or dealer
 in securities, or as an affiliate person, director or employee of any
 investment company, or engaging in or continuing any conduct or practice
in connection with such activity;

 ii. Engaging in any type of business practice;

 iii. Engaging in any activity in connection
with the purchase or sale of any security or commodity or in

 4. Was the subject of any order, judgment, or decree, not subsequently reversed, suspended, or vacated, of any federal or state authority barring, suspending, or otherwise limiting for more than 60 days the right of such person to engage in any such activity

 5. Was found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission to have violated any federal or state securities law, and the judgment in such civil action or finding by the Securities and Exchange Commission has not been subsequently reversed, suspended, or vacated.

 6. Was found by a court of
 competent jurisdiction in a civil action or by the Commodity Futures Trading
 Commission to have violated any federal commodities law, and the judgment in
 such civil action or finding by the Commodity Futures Trading Commission has not
 been subsequently reversed, suspended or vacated.

 Director Compensation

 We do not currently pay any compensation to our directors,
nor do we pay directors' expenses in attending board meetings.

 Employment Agreements

 The Company is not a party to any employment agreements.

 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 The following table sets forth, as of December 31, 2023, the
number and percentage of our outstanding shares of common stock owned by (i)
each person known to us to beneficially own more than 5% of our outstanding
common stock, (ii) each director, (iii) each named executive officer, and (iv)
all officers and directors as a group. Common stock beneficially owned and
percentage ownership was based on 876,090,000 shares outstanding on December 31,
2023.

 Shares of

 Percent of

 Percent of

 Series A

 Series A

 Number of

 Percent of

 Shares of

 Common

 Preferred

 Preferred

 Voting

 Voting

 Common

 Stock

 Stock

 Stock

 Shares

 Shares

 Stock Beneficially

 Name of Beneficial Owner

 Owned•

 Owned (1) **

 Owned

 Owned**

 Owned**

 Owned (1) **

 5% Beneficial Owners

ACFT LLC

 150,000,000

 17.12%

 —

 —

 —

 —

 Mariya S Radivoeva

 94,500,000

 10.79%

 —

 —

 —

 —

 Noble Investment Corp

 154,500,000

 17.64 %

 —

 —

 —

 —

 Kubrat Radivoev

 75,000,000

 8.56%

 —

 —

 —

 —

 Directors and Officers

 Dimitar Slavchev Savov

 322,120,000

 36.77%

 100%

 100,000,000

 43.25%

 Clifford Redekop

 —

 —

 —

 —

 —

 —

 All directors and
executive officers as a

group (2 persons)

 322,120,000

 36.77%

 100%

 100,000,000

 43.25%

 **

 Under SEC rules, beneficial ownership includes
 shares over which the individual or entity has voting or investment power
 and any shares which the individual or entity has the right to acquire
 within sixty days.

 (1)

 Percentage of voting stock is based on
 876,090,000 shares of our common stock and 10,000,000 shares of Series A
 Preferred Stock outstanding on March 17, 2023.

 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE

 The following information summarizes transactions we have
either engaged in for the past two fiscal years or propose to engage in,
involving our executive officers, directors, more than 5% stockholders, or
immediate family members of these persons. These transactions were negotiated
between related parties without "arm's length" bargaining and, as a result, the
terms of these transactions may be different than transactions negotiated
between unrelated persons.

 During the year ended December 31, 2022, Mr. Ray (former CEO)
loaned the Company $6,000.

 In conjunction with the sale of the majority shares of the
Company and the change in ownership, Mr. Ray forgave the $30,018 that was due to
him from the Company. The $30,018 has been credited to additional paid in
capital.

 During the years ended December 31, 2023 and 2022, Dimitar
Slavchev Savov, CEO, advanced the Company $83,565 and $24,180, respectively, to
pay for general operating expenses. As of December 31, 2023, the total amount
due to Mr. Savov is $101,745. The advance in non-interest bearing and due on
demand.

 Exclusive Rights Agreements

 On April 7, 2022, the Company signed with "VITAL FE" Joint
Stock Company ("VITAL") an Exclusive Rights Agreement for a term of 15 years for
the production and distribution of Thymus Nuclear Glycoprotein ("TNG"). VITAL
holds the technology to manufacture TNG and the intellectual property for Phase
III Clinical Trial on TNG, started in 1997 and completed in 1998 in Infectious
Diseases Hospital, Sofia on 20 patients suffering from AIDS in the advanced
stages of the disease. The results of the clinical trial show that TNG has a
significant place in the treatment of HIV. Under the terms of the agreement the
Company issued 8,000,000 shares of Preferred stock to be issued in the name of
Dimitar Slavchev Savov. Dimitar Savov is Managing Director and owner of 70%
stake in VITAL. The shares were valued based on the equivalent number of votes
for common shares. The 8,000,000,000 (8 billion) equivalent common shares were
valued at $0.0003, the last sale price for common shares, (as there is currently
no trading volume), for total non-cash expense of $2,400,000.

 On April 7, 2022, the Company signed with "MICAR 11" LTD.
("MICAR") an Exclusive Rights Agreement for a term of 15 years for the
production and distribution of two dietary supplements, namely Carotilen
and Physiolong. Carotilen is a dietary supplement in the form of
soft gelatin capsules that improves and regulates the metabolism of the
epithelial cells and protects them from degenerative alterations. It favorably
affects embryonic development; the regulation of the growth and division of the
cells; stimulates the growth of the bone tissue; favorably affects the function
of the gonads; increases and maintains high level of the immune system.
 Physiolong is a dietary food supplement in the form of hard gelatin
capsules, which serves as general stimulant for those in a period of
convalescence, as well as in situations of high mental and physical loads, and
for the recovery in sports. Under the terms of the agreement the Company issued
2,000,000 shares of Preferred stock to be issued in the name of Dimitar Slavchev
Savov. MICAR is wholly owned by Dimitar Savov and he acts as its Managing
Director. The shares were valued based on the equivalent number of votes for
common shares. The 2,000,000,000 (2 billion) equivalent common shares were
valued at $0.0003, the last sale price for common shares, (as there is currently
no trading volume), for total non-cash expense of $600,000.

 On August 31, 2022, the company signed an Exclusive Rights
Agreement with Dimitar Slavchev Savov through which Nika is appointed as an
exclusive representative for the production and sale of the dietary supplements
Hypocholestin, Dry Boza, Anthocylen C, Fructin, Biodetoxin, Sylimaron within the
territories of Europe, Asia, Africa, South America, North America and Australia.

 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 Audit Fees

 The following table presents the aggregate fees billed for
each of the last two fiscal years by Fruci & Associates II, PLLC, our
Independent Registered Public Accounting Firms, in connection with the audit of
our consolidated financial statements and other professional services rendered
by this accounting firm.

 2023

 2022

 Audit fees

 $

 11,000

 $

 —

 Audit related fees

 —

 —

 Tax fees

 —

 —

 All other fees

 —

 —

 Total fees

 $

 11,000

 $

 —

 Audit fees represent fees for professional services rendered
by our principal accountants for the audit of our annual financial statements
and review of the financial statements included in our Forms 10-Q or services
that are normally provided by our principal accountants in connection with
statutory and regulatory filings or engagements.

 Audit-related fees represent professional services rendered
for assurance and related services by the accounting firm that are reasonably
related to the performance of the audit or review of our financial statements
that are not reported under audit fees.

 Tax fees represent professional services rendered by the
accounting firm for tax compliance, tax advice, and tax planning.

 All other fees represent fees billed for products and
services provided by the accounting firm, other than the services reported for
the other three categories.

 Pre-Approval Policies

 Our board of directors approves the engagement of the auditor
before the firm renders audit and non-audit services. Our audit committee does
not rely on pre-approval policies and procedures.

 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT
SCHEDULES

 The following documents have been filed as part of this
report.

 Exhibit No.

 Description

 31.1

 -

 Rule
 13a14(a)/15d -14(a) Certification of Chief Executive Officer and
 Chief Financial Officer

 32.1

 -

 Section 1350 Certification of Chief
 Executive Officer and Chief Financial Officer

 101.INS*

 -

 Document(1)

 101.SCH*

 -

 Document(1)

 101.SCH*

 -

 Schema Document(1)

 101.CAL*

 -

 Calculation Linkbase Document(1)

 101.DEF*

 -

 Extension Definition Linkbase Document(1)

 101.LAB*

 -

 Linkbase Document(1)

 ITEM 16. 10-K SUMMARY

 None.

 Signatures

 Pursuant to the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.

 Nika Pharmaceuticals, Inc.

 Date: April 1, 2024

 By:

 /s/
 Dimitar Slavchev Savov

 Dimitar Slavchev Savov

 Chief Executive Officer, Director

 Date: April 1, 2024

 By:

 /s/ Clifford Redekop

 Clifford Redekop

 Director